H-076
9-Hydroxyrisperidone solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
InChI
1S/C23H27FN4O3/c1-14-17(23(30)28-9-2-3-19(29)22(28)25-14)8-12-27-10-6-15(7-11-27)21-18-5-4-16(24)13-20(18)31-26-21/h4-5,13,15,19,29H,2-3,6-12H2,1H3
InChI key
PMXMIIMHBWHSKN-UHFFFAOYSA-N
SMILES string
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCC(O)C5=N1
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
Quality Level
Gene Information
human ... DRD2(1813), HTR2A(3356)
storage temp.
−20°C
General description
A Snap-N-Spike® Reference Solution suitable to use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Also known as paliperidone, 9-Hydroxyrisperidone is sold under the brand name Invega, an atypical antipsychotic used for acute and maintenance treatment of schizophrenia. The drug is also the primary metabolite of risperidone, marketed as the atypical antipsychotic Risperdal®.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Risperdal is a registered trademark of Johnson & Johnson
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Possible paliperidone-induced neuroleptic malignant syndrome: a case report.
Armağan Özdemir et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E22-E23 (2012-10-06)
Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation.
Arun Kandasamy
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E17-E18 (2012-10-06)
Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
Chih-Sung Liang et al.
Journal of clinical psychopharmacology, 32(5), 720-721 (2012-08-29)
Treatment options for residual insomnia in schizophrenia.
Lone Baandrup et al.
Acta psychiatrica Scandinavica, 127(1), 81-82 (2012-10-31)
N Thavichachart et al.
International journal of clinical practice, 66(10), 969-975 (2012-09-22)
To examine the demographic and psychopathological characteristics of the treatment discontinuation group compared with patients who completed with paliperidone ER treatment for 6 months. A total of 984 patients meeting the DSM-IV criteria for schizophrenia who switched their antipsychotics were
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持